Effect of reboxetine on major depressive disorder in breast cancer patients: An open-label study

Journal of Clinical Psychiatry

Volumn 65, Issue 4, 2004, Pages 515-520

  Grassi, Luigi ^a   Biancosino, Bruno ^b   Marmai, Luciana ^b   Righi, Roberto ^b  

^a UNIVERSITY OF FERRARA   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; MORPHOLINE DERIVATIVE; REBOXETINE;

ADAPTIVE BEHAVIOR; ADULT; AGED; ARTICLE; BREAST TUMOR; CLINICAL TRIAL; COMPARATIVE STUDY; DEPRESSION; DRUG ADMINISTRATION; FEMALE; HOSPITALIZATION; HUMAN; MIDDLE AGED; PERSONALITY TEST; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE; QUALITY OF LIFE; TREATMENT OUTCOME;

ADAPTATION, PSYCHOLOGICAL; ADULT; AGED; ANTIDEPRESSIVE AGENTS; BREAST NEOPLASMS; DEPRESSIVE DISORDER; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; MORPHOLINES; PERSONALITY INVENTORY; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 2442545311     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v65n0410     Document Type: Article

References (51)

1. McDaniel JS, Musselman DL, Porter MR, et al. Depression in patients with cancer: diagnosis, biology, and treatment. Arch Gen Psychiatry 1995;52:89-99
2. Spiegel D. Cancer and depression. Br J Psychiatry 1996;168(suppl 30):109-116 (Pubitemid 26000493)
3. Sellick SM, Crooks DL. Depression and cancer: an appraisal of the literature for prevalence, detection, and practice guideline development for psychosocial interventions. Psychooncology 1999;8:315-333 (Pubitemid 29417487)
4. Chochinov HM. Depression in cancer patients. Lancet Oncol 2001;2:499-505 (Pubitemid 33586305)
5. Grassi L, Rosti G, Albieri G, et al. Depression and abnormal illness behavior in cancer patients. Gen Hosp Psychiatry 1989;11:404-411 (Pubitemid 19277812)
6. Spiegel D, Sands S, Koopman C. Pain and depression in patients with cancer. Cancer 1994;74:2570-2578 (Pubitemid 24320864)
7. Grassi L, Indelli M, Marzola M, et al. Depressive symptoms and quality of life in home-care-assisted cancer patients. J Pain Symptom Manage 1996;12:300-307 (Pubitemid 26362304)
8. Henrikkson MM, Isometsä ET, Hietanen PS, et al. Mental disorders in cancer suicides. J Affect Disord 1995;36:11-20 (Pubitemid 26020968)
9. Kissane DW, Bloch S, Burns WI, et al. Psychological morbidity in the families of patients with cancer. Psychooncology 1994;3:47-56
10. Evans DL, McCartney CF, Haggerty JH, et al. Treatment of depression in cancer patients is associated with better life adaptation: a pilot study. Psychosom Med 1988;50:72-76 (Pubitemid 18033498)
11. Costa D, Mogos I, Toma T. Efficacy and safety of mianserin in the treatment of depression of women with cancer. Acta Psychiatr Scand 1985;72(suppl 320):85-92 (Pubitemid 16219447)
12. van Heeringen K, Zivkov M. Pharmacological treatment of depression in cancer patients: a placebo-controlled study of mianserin. Br J Psychiatry 1996;169:440-443 (Pubitemid 126735798)
13. Razavi D, Allilaire JF, Smith M, et al. The effect of fluoxetine on anxiety and depression symptoms in cancer patients. Acta Psychiatr Scand 1996;94:205-210 (Pubitemid 26313295)
14. Holland JC, Romano SJ, Heiligenstein JH, et al. A controlled trial of fluoxetine and desipramine in depressed women with advanced cancer. Psychooncology 1998;7:291-300 (Pubitemid 28381139)
15. Fisch MJ, Loehrer PJ, Kristeller J, et al. Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier Oncology Group. J Clin Oncol 2003;21:1937-1943 (Pubitemid 46606381)
16. Pezzella G, Moslinger-Gehmayr R, Contu A. Treatment of depression in patients with breast cancer: a comparison between paroxetine and amitriptyline. Breast Cancer Res Treat 2001;70:1-10 (Pubitemid 33105097)
17. Theobald DE, Kirsh KL, Holtsclaw E, et al. An open-label, crossover trial of mirtazapine (15 and 30 mg) in cancer patients with pain and other distressing symptoms. J Pain Symptom Manage 2002;23:442-447 (Pubitemid 34463013)
18. Chaturvedi SK, Maguire P, Hopwood P. Antidepressant medications in cancer patients. Psychooncology 1994;3:57-60
19. Shuster JL, Stern TA, Greenberg D. Pros and cons of fluoxetine for the depressed cancer patient. Oncology 1992;6:45-55 (Pubitemid 23002459)
20. Cheer SM, Goa KL. Fluoxetine: a review of its therapeutic potential in the treatment of depression associated with physical illness. Drugs 2001;61:81-110 (Pubitemid 32108326)
21. Massana J, Moller HJ, Burrows GD, et al. Reboxetine: a double-blind comparison with fluoxetine in major depressive disorder. Int Clin Psychopharmacol 1999;14:73-80 (Pubitemid 29149865)
22. Wong EH, Sonders MS, Amara SG, et al. Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor. Biol Psychiatry 2000;47:818-829 (Pubitemid 30254055)
23. Versiani M, Amin M, Chouinard G. Double-blind, placebo-controlled study with reboxetine in inpatients with severe major depressive disorder. J Clin Psychopharmacol 2000;20:28-34 (Pubitemid 30056350)
24. Schatzberg AF. Clinical efficacy of reboxetine in major depression. J Clin Psychiatry 2000;61(suppl 10):31-38 (Pubitemid 30485423)
25. Andreoli V, Caillard V, Deo RS, et al. Reboxetine, a new noradrenaline selective antidepressant, is at least as effective as fluoxetine in the treatment of depression. J Clin Psychopharmacol 2002;22:393-399 (Pubitemid 34810329)
26. Lemke MR. Effect of reboxetine on depression in Parkinson's disease patients. J Clin Psychiatry 2002;63:300-304 (Pubitemid 34456356)
27. Carvalhal AS, de Abreu PB, Spode A, et al. An open trial of reboxetine in HIV-seropositive outpatients with major depressive disorder. J Clin Psychiatry 2003;64:421-424 (Pubitemid 36547286)
28. Tanum L. Reboxetine: tolerability and safety profile in patients with major depression. Acta Psychiatr Scand Suppl 2000;402:37-40 (Pubitemid 30395386)
29. Fleishaker JC, Francom SF, Herman BD, et al. Lack of effect of reboxetine on cardiac repolarization. Clin Pharmacol Ther 2001;70:261-269 (Pubitemid 32868490)
30. Tranter R, Healy H, Cattell D, et al. Functional effects of agents differentially selective to noradrenergic or serotonergic systems. Psychol Med 2002;32:517-524 (Pubitemid 34308795)
31. Ferguson JM, Wesnes KA, Schwartz GE. Reboxetine versus paroxetine versus placebo: effects on cognitive functioning in depressed patients. Int Clin Psychopharmacol 2003;18:9-14 (Pubitemid 36127055)
32. Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod CM, ed. Evaluation of Chemotherapeutic Agents. New York, NY: Columbia University Press; 1949:191-205
33. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
34. Derogatis LR. The Brief Symptom Inventory (BSI): Administration, Scoring and Procedures Manual. 3rd ed. Minneapolis, Minn: National Computer Systems; 1993
35. Watson M, Law M, dos Santos M, et al. The Mini-MAC: further development of the Mental Adjustment to Cancer Scale. J Psychosoc Oncol 1994;12:33-46 (Pubitemid 24362754)
36. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Nat Cancer Inst 1993;85:365-376 (Pubitemid 23073154)
37. National Institute of Mental Health. CGI: Clinical Global Impressions. In: Guy W, Bonato RR, eds. Manual for the ECDEU Assessment Battery, 2. Rev ed. Chevy Chase, Md: National Institute of Mental Health; 1970:12-1-12-16
38. Passik SD, Dugan W, McDonald MV, et al. Oncologists' recognition of depression in their patients with cancer. J Clin Oncol 1998;16:1594-1600 (Pubitemid 28175786)
39. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 2000;160:2101-2117 (Pubitemid 30482715)
40. Tiernan E, Casey P, O'Boyle C, et al. Relations between desire for early death, depressive symptoms and antidepressant prescribing in terminally ill patients with cancer. J R Soc Med 2002;95:386-390 (Pubitemid 34879402)
41. Ballenger JC, Davidson JRT, Lecrubier Y, et al. Consensus statement on depression, anxiety, and oncology. J Clin Psychiatry 2001;62(suppl 8):64-67 (Pubitemid 32429966)
42. Passik SD, Kirsh KL, Theobald D, et al. Use of a depression screening tool and a fluoxetine-based algorithm to improve the recognition and treatment of depression in cancer patients: a demonstration project. J Pain Symptom Manage 2002;24:318-327 (Pubitemid 35379714)
43. Grassi L, Malacarne P, Maestri A, et al. Depression, psychosocial variables and occurrence of life events among patients with cancer. J Affect Disord 1997;44:21-30 (Pubitemid 27261378)
44. Chochinov HM, Wilson KG, Enns M, et al. Depression, hopelessness, and suicidal ideation in the terminally ill. Psychosomatics 1998;39:366-370 (Pubitemid 28347787)
45. Watson M, Haviland JS, Greer S, et al. Influence of psychological response on survival in breast cancer: a population-based cohort study. Lancet 1999;354:1331-1336 (Pubitemid 29481628)
46. Dubini A, Bosc M, Polin V. Noradrenaline-selective versus serotonin-selective antidepressant therapy: differential effects on social functioning. J Psychopharmacol 1997;11(suppl 4):S17-S23 (Pubitemid 27526052)
47. Venditti LN, Arcelus A, Birnbaum H, et al. The impact of antidepressant use on social functioning: reboxetine versus fluoxetine. Int Clin Psychopharmacol 2000;15:279-289 (Pubitemid 30660963)
48. Vieta E, Colom F, Martinez-Aran A, et al. Reboxetine-induced hypomania [letter]. J Clin Psychiatry 2001;62:655-656
49. Strain JJ, Caliendo G, Himelein C. Using computer databases to predict and avoid drug-drug interactions in the cancer patient requiring psychotropics. Psychooncology 1998;7:321-332 (Pubitemid 28381142)
50. Schwartz L, Lander M, Chochinov HM. Current management of depression in cancer patients. Oncology 2002;16:1102-1110
51. Twillman RK, Manetto C. Concurrent psychotherapy and pharmacotherapy in the treatment of depression and anxiety in cancer patients. Psychooncology 1998;7:285-290 (Pubitemid 28381138)